Please check your internet connection and try again.
# Clobazam (oral formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
## Adult Dosing
* **Initiation:** 5 mg orally twice daily.
* **Titration:** Increase dose by 5 mg to 10 mg every week based on clinical response and tolerability, up to a maximum of 20 mg twice daily.
* **Maintenance:** Typical maintenance dose is 10 mg to 20 mg twice daily. Maximum recommended dose is 20 mg twice daily.
## Pediatric Dosing (2 to 18 years)
* **Initiation:** 2.5 mg orally twice daily.
* **Titration:** Increase dose by 2.5 mg to 5 mg every week based on clinical response and tolerability.
* **Maximum Dose:**
* For patients weighing less than 30 kg: Maximum recommended dose is 10 mg twice daily.
* For patients weighing 30 kg or more: Maximum recommended dose is 20 mg twice daily.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific doseadjustment guidelines are established, but consider starting at a lower dose and titrating slowly.
* **Renal Impairment:** No specific dose adjustment is recommended, but use with caution.
* **Concomitant Medications:** Dose reduction may be necessary when used with potent CYP3A4 inhibitors. Coadministration with certain CNS depressants may require dose adjustment. Consult specific interaction information.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, fatigue, irritability, aggression, abnormal behavior, upper respiratory tract infection, and pneumonia.
* **Serious:** Suicidal behavior and ideation, serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), dependence and withdrawal symptoms, respiratory depression, and paradoxical reactions.
## Key Drug Interactions
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, ritonavir):** Can increase clobazam concentrations, potentially leading to increased adverse effects. Dose reduction of clobazam may be necessary.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** Can decrease clobazam concentrations, potentially reducing efficacy. Dose increase of clobazam may be necessary.
* **CNS Depressants (e.g., opioids, alcohol, other sedatives):** Additive CNS depressant effects can lead to excessive sedation, respiratory depression, and potentially fatal outcomes.
* **Perampanel:** Increased risk of somnolence and dizziness. Clobazam dose reduction may be considered.
* **Valproic acid:** Coadministration can increase valproic acid concentrations; monitor valproic acid levels and adjust dose as needed.
## Monitoring
* Monitor for efficacy (reduction in seizure frequency).
* Monitor for adverse effects, particularly somnolence, behavioral changes, and withdrawal symptoms upon discontinuation.
* Monitor for signs of suicidal behavior or ideation.
* Monitor for severe skin reactions.
* When coadministering with valproic acid, monitor valproic acid levels.
## Clinical Pearls
* Clobazam should be tapered slowly when discontinuing to avoid withdrawal symptoms.
* Paradoxical reactions (e.g., increased seizures, aggression) may occur.
* Due to its long half-life, clobazam may accumulate, especially in elderly patients or those with hepatic impairment.
* Behavioral changes, including aggression and suicidal ideation, have been reported; careful monitoring is essential.
***
**Disclaimer:** This information is intended for healthcare professionals and does not replace comprehensive drug information resources. Always consult the most current prescribing information and professional guidelines before making clinical decisions.
